Amgen v. Apotex: Federal Circuit Oral Argument Scheduled for April 4, 2016

Amgen v. Apotex (pegfilgrastim)  •  Biosimilar News  •  Patent Dance  •  U.S. Biosimilar Litigation News

The Federal Circuit announced that oral argument for the Amgen v. Apotex appeal will be held on April 4, 2016. Apotex is seeking to overturn the district court’s injunction against marketing its biosimilar pegfilgrastim product until 180 days after Apotex provides notice of commercial marketing, previously covered here. The briefs and other filings are available here.

Big Molecule Watch will continue to track this case and other litigation involving the BPCIA, so check back for the latest news and analysis.

Download PDF

Comments are closed.